SCHEMBL23705376

SCHEMBL23705376

CC1(CO)COc2ccc(C(=O)O)cc21

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RARB P10826 9/20 0.51
RARG P13631 9/20 0.51
RARA P10276 7/20 0.51
CNR2 P34972 3/20 0.51
PTGS1 P23219 2/20 0.50
PTGS2 P35354 2/20 0.50
ALDH1A1 P00352 1/20 0.45
MAPK1 P28482 1/20 0.45
RXRA P19793 3/20 0.42
CYP26A1 O43174 2/20 0.40
CYP26B1 Q9NR63 2/20 0.40
TDP1 Q9NUW8 1/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
SRD5A2 P31213 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25514121 0.85 RARB (0.54) RARBRARGRARACNR2PTGS1
SCHEMBL3019867 0.83 CNR2 (0.71) RARBRARGRARACNR2PTGS1
SCHEMBL3542625 0.81 RARB (0.71) RARBRARGRARACNR2PTGS1
Hydrochloric Acid SCHEMBL11212968 0.80 RARB (0.69) RARBRARGRARACNR2PTGS1
SCHEMBL30042770 0.78 CA12 (0.39) RARBRARGRARAALDH1A1RXRA
SCHEMBL23705947 0.78 CA12 (0.39) RARBRARGRARAALDH1A1RXRA
SCHEMBL23705816 0.78 CA12 (0.39) RARBRARGRARAALDH1A1RXRA
SCHEMBL30041433 0.78 CA12 (0.39) RARBRARGRARAALDH1A1RXRA
SCHEMBL23705969 0.78 CA12 (0.39) RARBRARGRARAALDH1A1RXRA
SCHEMBL13668349 0.78 ALDH1A1 (0.53) RARBRARGRARACNR2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
CN-115484948-A Compound and use thereof 福宏治疗公司 2022-12-16 CN disclosed
EP-4096657-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB RARB 140/4885RARG 308/4885RARA 393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.